

MALIGNANT HYPERTHERMIA IN A PATIENT WITH SICKLE CELL ANEMIA*

*Aytemiz Gürgey MD**, Çiğdem Altay MD**, Saadet Özgen MD****

Key words: sickle cell anemia, malignant hyperthermia

Since as far as we know, there have been no previous reports in the literature describing the malignant hyperthermia syndrome (MHS) associated with sickle cell anemia, we decided to present a patient with sickle cell anemia who had developed malignant hyperthermia after receiving an anesthetic agent¹.

Case Report

A sixteen-year-old male with sickle cell anemia who had been seen at our hospital three or four times a year, had been experiencing painful crises over the last eight years.

Physical examination was unremarkable except for strabismus and the presence of hepatomegaly which was four cm below the right costal margin.

The hemoglobin level was stable at around 8 g/dl. The hemoglobin A₂ and hemoglobin F levels were two percent and nine percent, respectively. The remaining hemoglobin was Hb S. Both parents had Hb S traits.

At the age of sixteen, the patient was admitted to our hospital for surgical correction of strabismus. He was transfused until the Hb S level was fifteen percent. He was given succinylcholine and his temperature rose to 40°C within a few minutes, and surgery was cancelled. Cardiac arrest occurred, and the patient was resuscitated, cooled, and bicarbonate and prednisolone were administered intravenously. He recovered uneventfully within the following four to five hours. The serum creatinine phosphokinase level was found to be 18 units (normal: 8-12 units). A muscle biopsy revealed interstitial edema and a slight increase in fibrous tissue which were said to be characteristic of myopathy.

* From the Department of Pediatrics, Hacettepe University Faculty of Medicine.

** Professor of Pediatrics, Hacettepe University Faculty of Medicine.

*** Assistant Professor of Anesthesiology, Hacettepe University Faculty of Medicine.

Discussion

Malignant hyperthermia syndrome may develop after the use of general anesthetics such as succinylcholine and halothane^{2,3}. This condition has been reported to be fatal in 20-40 percent of patients⁴. In some patients treatment with hydantoin derivatives has proven to be effective³. Our patient recovered within a few hours, without the administration of any specific form of therapy.

In half of the MHS cases an autosomal dominant form of subclinical myopathy has been observed. The presence of nonspecific musculoskeletal abnormalities such as ptosis or strabismus have been reported in one third of patients with MHS⁵. In addition, an elevated serum creatinine phosphokinase level has been found in some MHS patients with associated myopathy.

The association of MHS with pseudohypertrophic muscular dystrophy, the King syndrome, the Noonan syndrome, and a few malignancies have been reported⁵⁻⁹. In some cases virus-like particles have been observed in muscle biopsies, suggesting a viral etiology of the condition¹⁰. A slight increase in the serum creatinine phosphokinase level and changes in muscle biopsy associated with strabismus suggest the presence of an inherited susceptibility to MHS in our patient. Although there have been no reports in the literature describing a case of sickle cell anemia associated with MHS, it is still not clear whether malignant hyperthermia coincides with sickle cell anemia or if sickle cell anemia patients are susceptible to MHS.

Summary

A sixteen-year-old male with sickle cell anemia and congenital strabismus developed malignant hyperthermia a few minutes after the administration of succinylcholine, used as the general anesthetic for corrective eye surgery. The patient's hemoglobin S level was reduced to fifteen percent before the operation. He recovered uneventfully within a few hours. Increased serum creatinine phosphokinase activity and pathological changes observed in the muscle biopsy along with strabismus suggest that the patient had an inherited susceptibility to malignant hyperthermia.

REFERENCES

1. Jama H, Gürgey A, Altay Ç. Alpha-thalassemia in a pool of individuals of Eti-Türk origin with hemoglobin S (Hb S). *Turk J Pediatr* 29:1, 1987.
2. King JO, Denborough MA, Phil D. Anesthetic-induced malignant hyperpyrexia in children. *J Pediatr* 83:37, 1973.
3. Nelson TE, Flewellen EH. The malignant hyperthermia syndrome. *N Engl J Med* 309:416, 1983.
4. Ellis FR. Malignant hyperpyrexia. *Arch Dis Child* 59:1013, 1984.

5. Steenson AJ, Torkelson RD. King's syndrome with malignant hyperthermia. Potential outbreak crisis. *Am J Dis Child* 141:271, 1987.
6. McPherson EW, Taylor CA Jr. The King syndrome: malignant hyperthermia, myopathy, and multiple anomalies. *Am J Med Genet* 8:159, 1981.
7. Hunter A, Pinsky L. An evaluation of the possible association of malignant hyperpyrexia with the Noonan syndrome using serum creatine phosphokinase levels. *J Pediatr* 86:412, 1975.
8. Tsueda K, Dubick MN, Wright BD, Sachatello CR. Intraoperative hyperthermic crisis in two children with undifferentiated lymphoma. *Anesth Analg* 57:511, 1978.
9. Simmons PS, Smithson WA, Gronert GA, Haymond MW. Acute myelogenous leukemia and malignant hyperthermia in a patient with type 1b glycogen storage disease. *J Pediatr* 105:428, 1984.
10. Schiller HH. Chronic viral myopathy and malignant hyperthermia [letter]. *N Engl J Med* 292:1409, 1975.